Pridopidine, from Israeli biotech Prilenia, has been chosen by the Healey Center at Massachusetts General hospital for the first-ever platform (multiple treatments) trial for amyotrophic lateral sclerosis (ALS). Prilenia is trialing Pridopidine for several neurodegenerative disorders.
https://www.prilenia.com/18-september-2019-pr
https://www.massgeneral.org/neurology/als/research/platform-trial